Nightstar Therapeutics PLC
(NASDAQ : NITE)

( )
NITE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
0.78%42.000.9%$967.82m
MRKMerck & Co., Inc.
1.86%80.980.6%$797.52m
JNJJohnson & Johnson
0.46%138.760.7%$772.80m
BMYBristol-Myers Squibb Company
0.64%47.741.4%$659.03m
LLYEli Lilly and Company
1.20%117.981.0%$500.32m
ABBVAbbVie, Inc.
0.90%81.612.2%$449.20m
AZNAstraZeneca PLC Sponsored ADR
2.01%38.641.3%$190.16m
NVSNovartis AG Sponsored ADR
1.88%83.940.2%$190.02m
GSKGlaxoSmithKline plc Sponsored ADR
2.03%40.190.2%$102.66m
NVONovo Nordisk A/S Sponsored ADR Class B
1.84%48.410.1%$64.13m
SNYSanofi Sponsored ADR
2.21%42.090.2%$48.51m
LCILannett Company, Inc.
-1.14%6.0636.7%$10.02m
AKTXAkari Therapeutics Plc Sponsored ADR
-4.74%2.411.6%$3.40m
EPIXESSA Pharma Inc
-6.51%2.010.1%$0.01m

Company Profile

Nightstar Therapeutics plc is a clinical-stage gene therapy holding company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.